Medical Care Technologies Inc. (OTCID:MDCE) Delivers Stronger Melanoma Scan Beta Readout on Expanded Human-Submitted Dataset
Internal testing recorded 84% end-to-end completion without manual intervention; the results do not establish clinical efficacy.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Medical Care Technologies (MDCE) published updated internal technical evaluation results for Melanoma Scan Beta using an expanded human-submitted image dataset.
In controlled sequential captures, 86% of newly submitted photographs met the usability threshold, 89% of usable images were successfully placed on the body map, and 91% of paired sequential images achieved alignment for visual review. End-to-end completion without manual intervention was 84%. The company reported higher usability and registration results than in its first pass.
The results assess image handling, mapping and comparison, not clinical efficacy. The product remains in beta development without regulatory clearance, and volunteer image intake remains open.
Positive
- Minor point84% end-to-end completion recorded without manual intervention in the expanded set of controlled sequential captures.
- Minor point86% usability pass rate for newly submitted photographs; the company reported improvement over its first pass.
- Minor point89% body-map registration among usable images; the company reported improvement over its first pass.
- Minor point91% alignment completion for paired sequential images supported side-by-side visual review under the internal protocol.
Negative
- None.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MESA, AZ / ACCESS Newswire / November 2, 2026 / Medical Care Technologies Inc. (OTCID:MDCE) today announced that updated internal evaluation results for MDCE Melanoma Scan Beta have been posted on the Company's corporate website.
The full technical summary is available at https://www.medicalcaretechnologies.com.
This release fulfills the Company's October 20 announcement that next-round results on the expanded human-submitted dataset would be published. The evaluation covers the same three technical layers previously described:
- Image intake and quality scoring -
86% of newly submitted user photographs met the internal usability threshold and advanced to further processing (held-out samples were primarily limited by extreme blur, severe underexposure, or incomplete framing). - Body-map registration -
89% of usable images were successfully placed on the interactive body map with sufficient landmark consistency to support later retrieval of the same skin area. - Change-over-time comparison -
91% of paired sequential images of a previously mapped area achieved alignment sufficient for side-by-side visual review under the Company's internal protocol.
These figures are drawn from the larger set of human-submitted images collected after the September 29 first-pass results. The first pass had confirmed that real-world photographs could move through the three layers. The current readout reflects continued testing against lighting, device, distance, angle, and compression variables that public archives (HAM10000, ISIC, TCIA) do not fully represent.
Sample internal metrics from the expanded set (controlled sequential captures):
| Layer | Metric | Result | Notes |
|---|---|---|---|
| Image quality | Usability pass rate | Above typical 75 | |
| Body-map | Successful registration | Landmark consistency sufficient for re-identification of mapped area | |
| Sequential comparison | Alignment completion | Paired images suitable for visual change review | |
| Overall workflow | End-to-end completion | Percentage of submissions that completed all three layers without manual intervention |
MDCE Melanoma Scan Beta remains in beta-stage development. It has not received regulatory clearance and is not intended to treat, cure, or prevent any disease or medical condition. It is not a substitute for professional medical advice, screening, or evaluation by a qualified healthcare provider. The results describe internal technical evaluation of image handling, mapping, and comparison only.
"The expanded set produced higher usability and registration numbers than the first pass," said Marshall Perkins, CEO of Medical Care Technologies. "These are internal technical results on photographs people actually take. Intake remains open so we can keep widening the test set."
Volunteer participation is not a clinical diagnosis program and is not a clinical efficacy trial. Any concern about a skin change should be reviewed by a licensed clinician.
About Medical Care Technologies Inc.
Medical Care Technologies Inc. (OTCID:MDCE) is a diversified technology company focused on the development and commercialization of artificial intelligence-powered applications spanning health, wellness, nutrition, lifestyle, and enterprise imaging analysis solutions. Visit: https://www.medicalcaretechnologies.com
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on current expectations and assumptions, and actual results may differ materially due to various risks and uncertainties. The company undertakes no obligation to update these statements except as required by law. Investors are cautioned not to place undue reliance on forward-looking statements.
Contact Information:
Medical Care Technologies Inc.
1910 S. Stapley Drive, Suite 221, Mesa, AZ 85204
Phone: +1 (480) 645-0750
Email: marshall@medicalcaretechnologies.com
Website: https://www.medicalcaretechnologies.com
SOURCE: Medical Care Technologies Inc.
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Medical Care Technologies report in its expanded Melanoma Scan Beta evaluation?
The internal evaluation recorded 86% image usability, 89% body-map registration among usable images, 91% alignment of paired sequential images and 84% end-to-end completion without manual intervention. These are technical workflow results, not clinical efficacy findings.
What prevented some photographs from passing MDCE Melanoma Scan Beta's image intake checks?
Photographs held out at intake were primarily limited by extreme blur, severe underexposure or incomplete framing. The usability threshold determined which newly submitted images advanced to further processing.